Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Merck & Co.
 More »

  • Biotechs Need to Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    5-15-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Drug and specific cancer indication not disclosed. Financial terms not disclosed. Abbott (Abbott Molecular) and Merck & Co. Agreement announced March 6, 2012 Collaboration to ...
    5-9-2013
  • Pharma Builds Bridges with Advocacy Groups
    ... Acorda's lines, while big pharma can be expected to expand wellness efforts, which include GlaxoSmithKline's Triple Solution for a Healthier America and Merck & Co.'s MerckEngage. ...
    5-7-2013
  • BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration
    The others include Astellas, Merck & Co., Eli Lilly, and several undisclosed partners. Companies will join to develop antibody drug conjugates for unspecified cancer indications ...
    5-3-2013
  • Merck Launches Up To $430M Diabetes Collaboration with Abide
    Merck & Co. entered into an up to $430 million collaboration with Abide Therapeutics to discover, develop, and commercialize small molecule therapies designed to treat type 2 ...
    5-2-2013
  • Merck Joins Pfizer to Develop Type 2 Diabetes Drug
    On the eve of Phase III trials expected to start later this year, Merck & Co. and Pfizer said today they will team up to develop and commercialize Pfizer's ertugliflozin ...
    4-29-2013
  • Theravance to Split Late-Stage Partnered Assets from Biopharma...
    In October, Merck & Co. licensed cardiovascular candidates from Theravance in a $5 million up-front deal. The firm plans to separate its late-stage partnered respiratory assets ...
    4-26-2013
  • GEN | Biolinks
    ... MBL McGill University Med Discovery SA Medicago Inc Medical Research Council Medicines for Malaria Venture MedImmune Medincell Corporation Medisyn Technologies, Inc Merck & Co. ...
  • Enzon Gives Up Hope to Sell
    Enzon's revenues consist of royalties on seven products, the majority of which come from sales of PegIntron (Peginterferon alfa-2b), the hepatitis C virus drug made by Merck & Co. ...
    4-24-2013
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    In June 2012, Massachusetts joined with Abbott, Biogen Idec, EMD Serono, Janssen, Merck & Co., Pfizer, and Sunovion Pharmaceuticals to form the Massachusetts Neuroscience ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... marketed in Colombia; Yisaipu, marketed in China Recently discontinued effort: Merck & Co. and Hanwha Chemical: Hanwha disclosed December 18, 2012, that Merck terminated ...
    4-22-2013
  • Merck & Co. Opens Third Manufacturing Plant in China
    Merck & Co. has opened a $120 million pharmaceutical plant in Hangzhou, China, that will serve as one of the pharma giant's manufacturing bases for the Asia-Pacific region. The ...
    4-19-2013
  • Merck & Co. Picks Up Exclusive Option on Xenon CV Drugs
    An affiliate of Merck & Co. has exercised its option to exclusively license from Xenon Pharmaceuticals small molecule compounds for a new, undisclosed target for potential ...
    4-17-2013
  • CEO Perks
    ... £914,000 ($1.406 million) 4 ; Base salary, £499,000 ($767,758) Kenneth C. Frazier Merck & Co., chairman, president, and CEO Perks and "all other" compensation: $56,374 in 2011 ...
    4-12-2013
  • Astellas, Ambrx Launch Up-To-$300M ADC Partnership
    In exchange, LinXis will receive undisclosed milestone payments and royalties. The deal with Astellas almost matches what Ambrx stands to receive from Merck & Co. in a ...
    4-5-2013

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll